690 Stock Overview
An investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Uni-Bio Science Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.052 |
| 52 Week High | HK$0.098 |
| 52 Week Low | HK$0.046 |
| Beta | -0.095 |
| 1 Month Change | -16.13% |
| 3 Month Change | -17.46% |
| 1 Year Change | -38.10% |
| 3 Year Change | -44.09% |
| 5 Year Change | -66.45% |
| Change since IPO | -89.29% |
Recent News & Updates
Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Dec 11
Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement
Sep 13Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive
Jul 29Recent updates
Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Dec 11Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement
Sep 13Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive
Jul 29Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive
May 27Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Apr 24Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%
Jan 22Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement
Oct 24Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)
Apr 30We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Nov 22Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)
Jan 05Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth
Mar 01Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years
Jan 05
We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Nov 23Shareholder Returns
| 690 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -16.1% | 2.2% | 4.3% |
| 1Y | -38.1% | 13.2% | 28.1% |
Return vs Industry: 690 underperformed the Hong Kong Biotechs industry which returned 13.2% over the past year.
Return vs Market: 690 underperformed the Hong Kong Market which returned 28.1% over the past year.
Price Volatility
| 690 volatility | |
|---|---|
| 690 Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.8% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 690 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 690's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 458 | Frank Zhao | www.uni-bioscience.com |
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes.
Uni-Bio Science Group Limited Fundamentals Summary
| 690 fundamental statistics | |
|---|---|
| Market cap | HK$310.50m |
| Earnings (TTM) | HK$98.86m |
| Revenue (TTM) | HK$508.40m |
3.1x
P/E Ratio0.6x
P/S RatioIs 690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 690 income statement (TTM) | |
|---|---|
| Revenue | HK$508.40m |
| Cost of Revenue | HK$83.85m |
| Gross Profit | HK$424.55m |
| Other Expenses | HK$325.70m |
| Earnings | HK$98.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.017 |
| Gross Margin | 83.51% |
| Net Profit Margin | 19.44% |
| Debt/Equity Ratio | 26.5% |
How did 690 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 01:55 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Uni-Bio Science Group Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.